This product is supplied strictly for laboratory research purposes and is intended solely for use by qualified researchers and professionals in controlled scientific settings
Stack 3: metabolic neuropathy support (BPC-157 + SS-31 or MOTS-c) For neuropathies with a strong metabolic component, particularly diabetic peripheral neuropathy, combining a direct nerve repair peptide with a mitochondrial support peptide addresses both the damage and its upstream metabolic cause
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
BPC-157 + GHK-Cu Skin and Connective Tissue GHK-Cu (copper peptide) promotes collagen synthesis and skin remodeling
Consultations are available by phone MondayFriday 9am5pm CST
The standard medical response to long COVID has largely followed the conventional playbook: refer to the appropriate specialist for each symptom
